No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
66 |
4. Check minimum number of eventsNone |
66 |
5. Include endpointsNone |
66 |
6. Filter based on genotype QC (FinnGen only) |
61 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Kidney diseases associated to Fabry's disease
based on the number of shared cases.
Similar with more cases:
- Sphingolipidosis, other/unspecified
- Disorders of sphingolipid metabolism and other lipid storage disorders
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 61 | 47 | 14 |
| Unadjusted period prevalence (%) | 0.01 | 0.02 | 0.01 |
| Median age at first event (years) | 49.86 | 51.01 | 46.00 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 66
- Matched controls
- 660
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E75.2
ICD-10 Finland
Other sphingolipidosis
+∞
84.9
62
*
N08.4*E75.2
ICD-10 Finland
Glomerular disorders in Fabry(-Anderson) disease
+∞
23.3
21
*
Z31.5
ICD-10 Finland
Genetic counselling
19.6
16.8
26
21
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
8.6
15.8
27
49
195
Kela drug reimbursment
Agalsidase alfa, agalsidase beta and migalastat
+∞
12.9
12
*
FM1DG
NOMESCO Finland
Very extensive MRI examination of heart with high intesity magnet
79.5
12.1
13
*
336
Kela drug reimbursment
Agalsidase alfa, agalsidase beta and migalastat
+∞
11.8
11
*
Z01.1
ICD-10 Finland
Examination of ears and hearing
6.4
10.1
21
45
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
9.4
9.5
20
29
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
5.0
8.6
25
72
XF402
NOMESCO Finland
ECG with work load test
10.2
8.2
16
20
151
Kela drug reimbursment
Eliglustat, imiglucerase and velaglucerase alfa
+∞
7.4
7
*
6AB04, ,
NOMESCO Finland
+∞
7.4
7
*
FM1CG
NOMESCO Finland
Extensive examination of hear with high intensity magnet
+∞
7.4
7
*
A16AB04
ATC
agalsidase beta; parenteral
+∞
7.4
7
*
333
Kela drug reimbursment
Eliglustat, imiglucerase and velaglucerase alfa
+∞
7.4
7
*
XF404
NOMESCO Finland
Ambulatory ECG
8.4
7.4
16
24
TPH04
NOMESCO Finland
Cathetrisation of vein
4.7
7.3
22
64
Z01.8
ICD-10 Finland
Other specified special examinations
4.4
7.2
24
76
ZX120
NOMESCO Finland
Intravenous
6.9
7.1
18
34
FP4B5
NOMESCO Finland
ECG, prolonged recording (24 h)
+∞
6.3
6
*
I42.2
ICD-10 Finland
Other hypertrophic cardiomyopathy
+∞
6.3
6
*
E75.3
ICD-10 Finland
Sphingolipidosis, unspecified
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
28
9
52.45
23.98
4.7
2.8
1.36
1.05
mg/l
—
28
9
50
177
8.53
15.04
6.6
4.3
37.56
36.18
g/l
1.07
50
167
40
124
6.65
13.50
5.5
3.7
9.89
5.63
mg/mmol
0.29
32
79
21
35
8.33
13.05
4.3
1.8
82.85
79.20
ml/min/173m2
0.11
13
15
46
209
4.96
8.80
4.4
2.1
74.46
76.77
nmol/l
0.30
46
187
38
156
4.38
8.17
4.0
3.0
30.77
25.80
ng/l
0.22
26
94
36
162
3.69
6.41
4.1
2.7
—
—
—
0
0
10
16
7.15
4.49
4.9
2.8
22.95
25.36
mmol/l
—
10
16
7
9
8.53
3.65
7.9
1.2
—
—
—
0
0
36
207
2.63
3.61
14.1
7.4
1.22
1.22
mmol/l
0.14
30
180
7
10
7.67
3.45
3.7
4.0
55.29
57.80
%
—
7
10
8
15
5.90
3.30
7.1
1.1
—
—
—
0
0
10
26
4.34
3.13
3.9
1.7
1.25
2.69
mg/l
—
10
17
6
10
6.47
2.76
8.3
1.2
0.00
0.00
g/l
—
6
10
15
66
2.65
2.46
7.0
4.2
0.83
0.82
mmol/l
0.09
15
60
16
73
2.57
2.45
3.3
2.5
1.65
2.71
e6/l
0.31
11
41
17
84
2.38
2.20
3.2
2.4
0.61
0.77
e6/l
0.23
12
52
7
21
3.60
2.03
5.7
1.8
4.83
5.15
kpa
—
7
21
28
176
2.03
2.00
19.4
12.1
1.42
1.20
inr
—
5
57
27
184
1.79
1.43
1.9
1.8
97.19
100.40
pmol/l
0.14
15
94
35
266
1.67
1.21
3.7
3.2
0.00
0.00
estimate
—
7
52
8
39
2.19
1.20
2.6
7.0
105.88
103.79
mmol/l
—
8
39
35
267
1.66
1.19
5.4
4.4
0.00
0.00
estimate
—
7
47
5
20
2.62
1.17
1.4
1.6
—
—
—
0
0
8
40
2.14
1.16
2.9
2.3
268.00
374.63
nmol/l
—
8
35
35
271
1.62
1.09
3.7
3.1
0.00
0.00
estimate
—
6
45
12
68
1.93
1.09
1.3
1.5
—
—
—
0
0
7
126
0.50
1.02
2.3
2.6
—
—
—
0
0
0
31
0.00
0.99
0.0
1.5
—
213.42
—
0
17
8
43
1.98
0.91
4.4
2.8
—
—
—
0
0
7
119
0.54
0.77
2.1
2.4
—
—
—
0
0
56
510
1.65
0.68
19.4
9.1
84.53
86.63
ml/min/173m2
0.20
50
397
5
28
1.85
0.67
4.0
1.4
—
—
—
0
0
8
50
1.68
0.64
1.5
1.5
—
—
—
0
0
8
51
1.65
0.63
1.5
1.5
—
—
—
0
0
0
19
0.00
0.61
0.0
1.3
—
—
—
0
0
59
555
1.59
0.54
19.7
10.7
22.19
20.11
mg/l
0.17
43
399
14
104
1.44
0.48
1.6
2.1
—
—
—
0
0
0
15
0.00
0.42
0.0
1.8
—
739.84
—
0
15
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
51
474
1.33
0.37
7.4
4.7
37.81
38.46
mmol/mol
0.26
51
442
6
44
1.40
0.35
2.2
1.8
40.00
27.81
u/l
—
6
36
11
141
0.74
0.34
1.4
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
7
62
1.14
0.18
4.6
6.2
—
—
—
0
0
5
68
0.71
0.18
3.2
2.1
—
—
—
0
0
25
233
1.12
0.11
2.0
2.7
—
—
—
0
0
8
75
1.08
0.08
3.9
5.3
1.25
2.40
ug/l
—
8
64
23
217
1.09
0.07
4.2
3.1
—
—
—
0
0
13
142
0.89
0.07
1.7
1.7
—
—
—
0
0
38
389
0.95
0.03
3.4
3.7
—
—
—
0
0
15
142
1.07
0.03
4.5
3.4
0.00
0.00
estimate
—
6
48
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
2.9
—
22.88
—
0
8
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: E4_FABRY_KIDNEY – Kidney diseases associated to Fabry's disease
GWS hits: 2
This endpoint is excluded (different definition than used in FinnGen).